EUCTR2017-001156-55-PL进行中（未招募）1 期
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-Weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease
Pfizer Inc. 235 East 42nd Street, New York, NY 100170 个研究点目标入组 305 人开始时间: 2017年9月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 305
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects between the ages of 18 (or the minimum country-specific age of consent if > 18) and 70 years, inclusive, at Visit 1 (Screen 1):
- •Male and female subjects of childbearing potential must agree to use highly effective method(s) of contraception.
- •Female subjects of childbearing potential must not be pregnant, breastfeeding, or planning to become pregnant for the duration of their participation in this study and within 28-days following last dose of blinded investigational product.
- •Female subjects of non-childbearing potential must meet at least 1 of the following criteria:
- •a. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state, with a single repeat assessment, via the sponsor-identified central laboratory, permitted to assess postmenopausal state, if needed;
- •b. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- •c. Have medically confirmed ovarian failure;
- •All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
- •At Pre-Qualification and Visit 1 (Screen 1), in all female subjects, serum beta human chorionic gonadotropin (ß-hCG) level, with a single repeat assessment, via the sponsor-identified central laboratory, permitted to assess non-pregnant state, if needed.
- •2. At Pre-Qualification, pass the hula-hoop test with a single repeat assessment, permitted, if needed, to assess eligibility.
- •3. At Pre-Qualification, have an arm circumference compatible with the largest blood pressure cuff size available at individual sites with a single repeat assessment, permitted, if needed, to assess eligibility.
- •4. At Pre-Qualification and Visit 1 (Screen 1), total body weight of > 50 kg (110 lbs) with BMI = 25 kg/m2 (for sites in Africa, Europe, North America) or BMI = 22.5 kg/m2 (for sites in Asia), with a single repeat assessment of body weight and/or BMI permitted to assess eligibility, if needed, at each of these 2 visits.
- •5. At Pre-Qualification and Visit 1 (Screen 1), meet the following criteria for liver fat, based on assessment via FibroScan®, with a single repeat permitted to assess eligibility, if needed, at each of these 2 visits:
- •CAPTM = 280 dB/m;
- •6. At Pre-Qualification and Visit 1 (Screen 1), meet the following criteria, as assessed by sponsor-identified central laboratory; with a single repeat on any of these parameters permitted to assess eligibility, if needed, at each of these 2 visits:
- •International Normalized Ratio (INR) = 1.3;
- •Albumin = lower limit of normal (LLN);
- •Platelet count = 0.95x LLN;
- •Fasting triglycerides = 400 mg/dL (4.5 mmol/L);
- •HbA1C = 9.5%;
- •Fasting plasma glucose = 270 mg/dL (15.0 mmol/L);
- •Total bilirubin < 1.5x upper limit of normal (ULN) and direct bilirubin = ULN.
- •7. Documented liver biopsy = 24-months prior to Visit 1 (Screen 1) with histological evidence of NASH in order to be classified in the sub-population with biopsy-proven NASH, only.
- •8. In those without biopsy-proven NASH, only, at Pre-Qualification and Visit 1 (Screen 1), meet the following criteria for liver stiffness, based on assessment via FibroScan®, with a single repeat permitted to assess eligibility, if needed, at each of these 2 visits:
- •LSM = 7.0 kPa – classified as p
排除标准
- •1. Subjects with known prior participation (ie, randomized and received at least 1 dose of investigational product) in a trial involving PF-05221304.
- •2. Participation in other studies involving investigational drug(s) within 30-days prior to Visit 1 (Screen 1) and during study participation (ie, up to 2nd Follow-up).
- •3. At Pre-Qualification and Visit 1 (Screen 1), history of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor)] within the previous 6 months.
- •4. At Pre-Qualification and Visit 1 (Screen 1), a total score of = 8 on the AUDIT questionnaire, indicating harmful or hazardous ethanol consumption.
- •5. At Pre-Qualification and Visit 1 (Screen 1), a positive urine drug test for illicit drugs.
- •6. At Pre-Qualification and Visit 1 (Screen 1), a persistent severe, uncontrolled
- •hypertension; for example: seated systolic blood pressure (SBP) =180 mm Hg and/or diastolic blood pressure (DBP) = 105 mm Hg after = 5-minute of rest, with a single repeat permitted to assess eligibility, if needed, at each of these 2 visits:
- •For subjects with SBP = 160 mm Hg or DBP = 100 mm Hg, the Run-in Period must be used to refine the doses of the agents used for management of blood pressure with the aim to have SBP = 159 mm Hg and DBP = 99 mm Hg at the time of randomization;
- •7. At Pre-Qualification and Visit 1 (Screen 1), a supine 12-lead ECG demonstrating QTc interval >450 msec or a QRS interval >120 msec:
- •If QTc interval exceeds 450 msec, or QRS interval exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc intervals or QRS intervals should be used to determine the subject’s eligibility.
- •8. At Pre-Qualification and Visit 1 (Screen 1), clinical evidence of hepatic decompensation, including, but not limited to esophageal varices, ascites or hepatic encephalopathy.
- •9. At Pre-Qualification and Visit 1 (Screen 1), evidence of other forms of chronic liver disease including but not limited to the entities listed below; evidence may include laboratory tests, as assessed by the sponsor-identified central laboratory, with a single repeat permitted to assess eligibility, if needed, at each of those two visit:
- •Hepatitis B virus (HBV), defined by presence of hepatitis B surface antigen (HBsAg);
- •Hepatitis C virus (HCV), defined by presence of hepatitis C antibody (HCVAb) irrespective of HCV RNA result (when reflexed based on a positive result for HCVAb);
- •Human Immunodeficiency Virus (HIV) infection, defined as presence of HIV antibody;
- •Known diagnosis of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, or overlap syndrome;
- •Alcoholic liver disease, as evaluated via history along with laboratory tests including serum % carbohydrate deficient transferrin result = 1.5x ULN deemed to be highly suggestive to alcohol abuse;
- •History of genetic reason for fatty liver;
- •Wilson's disease, defined as ceruloplasmin level < LLN;
- •Known diagnosis of hemochromatosis;
- •Alpha-1-antitrypsin (A1AT) deficiency, defined as alpha-1-antitrypsin level < LLN;
- •Prior known drug-induced liver injury;
- •Known or suspected Hepatocellular Carcinoma or other liver cancer;
- •History of liver transplant, current placement on a liver transplant list, or current model of end-stage liver disease (MELD) score >12;
- •Histological pre
研究者
相似试验
已完成
2 期
Study of ZYN002 (transdermal gel) in Patients with Partial Onset SeizuresNeurological - EpilepsyEpilepsyACTRN12616000510448Zynerba Pharmaceuticals Pty Ltd210
已完成
2 期
Study of ZYN002 (transdermal gel) in Patients with Knee Pain due to OsteoarthritisMusculoskeletal - OsteoarthritisOsteoarthritisACTRN12616001104448Zynerba Pharmaceuticals Pty Ltd320
招募中
2 期
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy.Neurological - EpilepsyEpilepsyACTRN12621000033842ES Therapeutics Australia Pty Ltd24
进行中（未招募）
1 期
The purpose of this trial is to assess dose related safety, early efficacy, pharmacokinetics and pharmacodynamics of INT-787 in patients with severe alcohol-associated hepatitis (sAH).Severe Alcohol-Associated HepatitisMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871EUCTR2022-001639-10-FRIntercept Pharmaceuticals, Inc.50
进行中（未招募）
1 期
A Study of JNJ-38518168 in Symptomatic Adult Participants with Uncontrolled, Persistent AsthmaAsthmaMedDRA version: 17.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855EUCTR2012-004920-39-DEJanssen-Cilag International N.V.160